Summary
Regeneron Pharmaceuticals, Inc. has filed a Current Report on Form 8-K to provide preliminary insights into its second quarter 2024 financial results. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $24 million. This charge, stemming from collaboration and licensing agreements, is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the quarter. While these figures are preliminary and subject to closing procedures, they offer investors an early look at a specific cost impacting the quarter's profitability.
Key Highlights
- 1Regeneron anticipates an approximate $24 million pre-tax acquired IPR&D charge for Q2 2024.
- 2This charge is related to up-front payments and equity premiums from collaboration and licensing agreements.
- 3The acquired IPR&D charge is expected to reduce Q2 2024 GAAP and non-GAAP net income per diluted share by roughly $0.18.
- 4The company notes that acquired IPR&D charges are variable and not typically forecasted due to uncertainty in timing and magnitude.
- 5The reported financial results for Q2 2024 are preliminary and subject to closing procedures.
- 6The filing includes forward-looking statements and a disclaimer regarding their reliability and the company's obligation to update them.
- 7A note explains the company's use of non-GAAP financial measures and their limitations.